Dayse Maria Lourenço
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dayse Maria Lourenço has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- André Pedrinelli
Universidade de São Paulo, Brazil
1 shared publication - Durval Ribas Filho
ABRAN - Associação Brasileira de Nutrologia/Brazilian Association of Nutrology, Catanduva, Sao Paulo, Brazil / UNIFIPA- Centro Universitário Padre Albino/ Padre Albino University Center, Medicine Course, Catanduva, Sao Paulo, Brazil
1 shared publication - Glaucia Carneiro
Universidade Federal de São Paulo
1 shared publication - Gustavo Loureiro
Fleury Laboratory, Brazil
1 shared publication - Henry Dan Kiyomoto
Physiotherapy Department, Faculdade das Americas, São Paulo, Brazil
1 shared publication - João Toniolo Neto
Federal University of São Paulo, São Paulo, Brazil
1 shared publication
Latest Publications
- Open Access
- 20 December 2024
- Published by Zotarelli-Filho Scientific Works in International Journal of Nutrology
- Vol. 18 (1)
Recommendations and guidance on Cobalamin (Vitamin B12) based on the Delphi method
Introduction: Vitamins are essential micronutrients for the body to function. Cobalamins (Cbls) are watersoluble compounds, acting as cofactors in enzymatic reactions. However, the use of Cbls in the clinical environment is still controversial. Objective: It was to discuss the topic and help guide different professionals, experts were brought together to discuss criteria concerning the diagnosis, indications, and use of cobalamin. Methods: The study was carried out using the Delphi method. Topics were initially created to direct the discussion and initial contributions. In the first meeting with the panelists, questions were formulated. The questions were distributed to all panelists. With the contributions, a text with the answers was created, and a third round to review the contributions and agree with the text was carried out. Results: The main topics related to the use of cobalamin were identified. Conclusion: The main topics related to this topic include risk groups of deficiency of ingestion or absorption by the gastrointestinal tract. The deficiency diagnosis must be made through laboratory tests, and early indication must be made when a significant cobalamin deficiency is identified, to avoid irreversible clinical conditions. A recommended practice is monitoring between 2 and 6 months after starting cobalamin replacement. Evidence Level:6.
- 20 December 2024
- Published by Zotarelli-Filho Scientific Works in International Journal of Nutrology
- Vol. 18 (1)
Open AccessRecommendations and guidance on Cobalamin (Vitamin B12) based on the Delphi method
Introduction: Vitamins are essential micronutrients for the body to function. Cobalamins (Cbls) are watersoluble compounds, acting as cofactors in enzymatic reactions. However, the use of Cbls in the clinical environment is still controversial. Objective: It was to discuss the topic and help guide different professionals, experts were brought together to discuss criteria concerning the diagnosis, indications, and use of cobalamin. Methods: The study was carried out using the Delphi method. Topics were initially created to direct the discussion and initial contributions. In the first meeting with the panelists, questions were formulated. The questions were distributed to all panelists. With the contributions, a text with the answers was created, and a third round to review the contributions and agree with the text was carried out. Results: The main topics related to the use of cobalamin were identified. Conclusion: The main topics related to this topic include risk groups of deficiency of ingestion or absorption by the gastrointestinal tract. The deficiency diagnosis must be made through laboratory tests, and early indication must be made when a significant cobalamin deficiency is identified, to avoid irreversible clinical conditions. A recommended practice is monitoring between 2 and 6 months after starting cobalamin replacement. Evidence Level:6.